PEAK6 Investments’s Intellia Therapeutics NTLA Stock Holding History

PEAK6 Investments’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$582K	Buy	28,300 +11,300	+66%	+$261K	﹤0.01%	2225
2024 Q2	$380K	Hold	17,000	–	–	﹤0.01%	2401
2024 Q1	$468K	Sell	17,000 -9,000	-35%	-$250K	﹤0.01%	2491
2023 Q4	$793K	Buy	+26,000	New	+$747K	﹤0.01%	2274
2023 Q2	–	Sell	-7,500	Closed	-$280K	–	4445
2023 Q1	$280K	Buy	+7,500	New	+$294K	﹤0.01%	2861
2022 Q3	–	Sell	-23,300	Closed	-$1.21M	–	5746
2022 Q2	$1.21M	Buy	23,300 +4,100	+21%	+$208K	﹤0.01%	2889
2022 Q1	$1.4M	Buy	+19,200	New	+$1.63M	﹤0.01%	2186
2021 Q3	–	Sell	-20,500	Closed	-$3.32M	–	5569
2021 Q2	$3.32M	Buy	+20,500	New	+$1.6M	0.01%	1429

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PEAK6 Investments's NTLA Position: Q3 2024 in Review

PEAK6 Investments sold out of Intellia Therapeutics (NTLA) in Q3 2024, closing a stake of 3,143 shares — an estimated $72.5K sold.

PEAK6 Investments first reported a position in NTLA in Q2 2021 and held it in 4 quarters. The position peaked at $372K in Q1 2024. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

PEAK6 Investments reported no remaining Intellia Therapeutics position as of Q3 2024 after selling out during the quarter.
PEAK6 Investments sold 3,143 Intellia Therapeutics shares in Q3 2024, an estimated $72.5K.
PEAK6 Investments first reported a position in Intellia Therapeutics in Q2 2021 and held it in 4 quarters.
PEAK6 Investments's Intellia Therapeutics position peaked at $372K in Q1 2024.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.